

Kerry A Rogers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/358300/publications.pdf>

Version: 2024-02-01

80
papers

2,690
citations

279798

23
h-index

189892

50
g-index

80
all docs

80
docs citations

80
times ranked

2582
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018, 379, 2517-2528.	27.0	706
2	<i>BTK</i> -Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 1437-1443.	1.6	367
3	Hypertension and incident cardiovascular events following ibrutinib initiation. <i>Blood</i> , 2019, 134, 1919-1928.	1.4	155
4	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. <i>Blood Advances</i> , 2017, 1, 1739-1748.	5.2	123
5	The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. <i>Cancer Discovery</i> , 2018, 8, 1300-1315.	9.4	115
6	Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. <i>Blood</i> , 2018, 132, 1568-1572.	1.4	100
7	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3626-3637.	1.6	71
8	Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. <i>Leukemia</i> , 2019, 33, 2527-2530.	7.2	65
9	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 2765-2775.	1.4	63
10	Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations. <i>Blood</i> , 2019, 134, 504-504.	1.4	57
11	A single-institution retrospective cohort study of first-line EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. <i>British Journal of Haematology</i> , 2018, 180, 259-266.	2.5	53
12	Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. <i>Blood Advances</i> , 2020, 4, 4648-4652.	5.2	53
13	Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2364-2373.	3.5	53
14	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021, 138, 1768-1773.	1.4	53
15	Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations. <i>Blood</i> , 2020, 135, 2192-2195.	1.4	40
16	Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. <i>Blood</i> , 2021, 137, 3473-3483.	1.4	40
17	The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. <i>Blood</i> , 2021, 138, 2372-2382.	1.4	35
18	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 17.	17.0	31

#	ARTICLE	IF	CITATIONS
19	Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1008-1011.	1.3	29
20	Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. <i>Blood</i> , 2022, 139, 686-689.	1.4	29
21	Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib. <i>Blood Advances</i> , 2019, 3, 116-118.	5.2	28
22	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	7.2	28
23	Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center. <i>Blood</i> , 2017, 130, 830-830.	1.4	27
24	Secondary autoimmune cytopenias in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016, 43, 300-310.	2.2	26
25	Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 688-698.	1.4	26
26	Use of <sc>PD</sc>-1 (<sc>PDCD</sc>1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre. <i>British Journal of Haematology</i> , 2019, 185, 363-366.	2.5	22
27	Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study. <i>American Journal of Hematology</i> , 2022, 97, 691-699.	4.1	19
28	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. <i>Blood</i> , 2018, 132, 6-6.	1.4	18
29	Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. <i>Haematologica</i> , 2021, 106, 2845-2852.	3.5	18
30	É½4-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6260-6273.	7.0	17
31	Ibrutinib and fungus: an invasive concern. <i>Blood</i> , 2018, 131, 1882-1884.	1.4	15
32	Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 693-693.	1.4	15
33	Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists. <i>Blood Advances</i> , 2020, 4, 4860-4863.	5.2	14
34	Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. <i>Clinical Cancer Research</i> , 2022, 28, 3242-3247.	7.0	14
35	Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 9-10.	1.4	12
36	Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment. <i>Blood</i> , 2018, 132, 2305-2305.	1.4	11

#	ARTICLE	IF	CITATIONS
37	Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). <i>Clinical Cancer Research</i> , 2022, 28, 603-608.	7.0	11
38	Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. <i>British Journal of Haematology</i> , 2019, 187, 399-402.	2.5	10
39	A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2951-2951.	1.4	10
40	The E μ -Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing. <i>Blood</i> , 2015, 126, 2752-2752.	1.4	8
41	Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	17.0	7
42	LC-FACSeq is a method for detecting rare clones in leukemia. <i>JCI Insight</i> , 2020, 5, .	5.0	6
43	Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study. <i>Blood</i> , 2018, 132, 3612-3612.	1.4	6
44	Evaluation of allogeneic and autologous membrane-bound IL-21 α -expanded NK cells for chronic lymphocytic leukemia therapy. <i>Blood Advances</i> , 2022, 6, 5641-5654.	5.2	6
45	Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients. <i>Blood</i> , 2022, 140, 401-405.	1.4	6
46	<p>Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 11743-11749.	1.9	5
47	Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax. <i>Current Medical Research and Opinion</i> , 2021, 37, 1409-1420.	1.9	5
48	A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2018, 132, 3136-3136.	1.4	5
49	Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia. <i>Blood</i> , 2016, 128, 1259-1259.	1.4	5
50	Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes. <i>Blood Advances</i> , 2022, 6, 5124-5127.	5.2	5
51	Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study. <i>Blood</i> , 2019, 134, 4310-4310.	1.4	4
52	Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver. <i>Cancer Cell</i> , 2016, 29, 3-4.	16.8	3
53	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 6187-6195.	7.0	3
54	Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 716-721.	1.3	3

#	ARTICLE	IF	CITATIONS
55	Optimizing extracellular vesicles™ isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant. JCI Insight, 2021, 6, .	5.0	3
56	Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study. Blood, 2019, 134, 3518-3518.	1.4	3
57	Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia. Blood, 2016, 128, 5598-5598.	1.4	3
58	Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib. Blood, 2021, 138, 3731-3731.	1.4	3
59	Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib. Leukemia, 2022, 36, 2129-2131.	7.2	3
60	A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia. Blood, 2019, 134, 3049-3049.	1.4	2
61	Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center. Blood, 2016, 128, 2040-2040.	1.4	2
62	Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL. Blood, 2016, 128, 4385-4385.	1.4	2
63	A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. Blood, 2016, 128, 4388-4388.	1.4	2
64	Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: Results from a Phase Ib Study. Blood, 2021, 138, 2631-2631.	1.4	2
65	Is less equal with ibrutinib dose?. Blood, 2018, 132, 2211-2212.	1.4	1
66	Antiemetic medication efficacy during EPOCH and R-EPOCH treatment. Journal of Oncology Pharmacy Practice, 2020, 27, 107815522096772.	0.9	1
67	Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies. Blood, 2018, 132, 4423-4423.	1.4	1
68	Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy. Blood, 2019, 134, 3045-3045.	1.4	1
69	Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Blood, 2020, 136, 2-3.	1.4	1
70	Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment. Blood, 2018, 132, 4143-4143.	1.4	1
71	Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 22-23.	1.4	1
72	Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy. Blood, 2020, 136, 29-30.	1.4	1

#	ARTICLE	IF	CITATIONS
73	A CAPTIVATE-ing new regimen for CLL. <i>Blood</i> , 2022, 139, 3229-3230.	1.4	1
74	Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance). <i>Leukemia and Lymphoma</i> , 2019, 60, 2580-2583.	1.3	0
75	Collectively Answering the Venetoclax BTK Inhibitor Sequencing Question in CLL. <i>Clinical Cancer Research</i> , 2020, 26, 3501-3502.	7.0	0
76	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2021, 35, 3287-3290.	7.2	0
77	Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration. <i>Blood</i> , 2018, 132, 1648-1648.	1.4	0
78	Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events. <i>Blood</i> , 2018, 132, 1845-1845.	1.4	0
79	Restoring Functional Deficits in Older Adults with Hematologic Malignancy. <i>Blood</i> , 2019, 134, 4776-4776.	1.4	0
80	LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia. <i>Blood</i> , 2019, 134, 3377-3377.	1.4	0